Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin

American Journal of Ophthalmology

Volumn 143, Issue 6, 2007, Pages

  Chan, Wai Man ^a,b,c   Lai, Timothy Y Y ^a   Liu, David T L ^b   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CATARACT; CENTRAL SEROUS RETINOPATHY; CHOROID DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FOVEA; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 34248570524     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.02.039     Document Type: Article

References (34)

1. Green W.R., and Wilson D.J. Choroidal neovascularization. Ophthalmology 93 (1986) 1169-1176
2. Grossniklaus H.E., and Green W.R. Choroidal neovascularization. Am J Ophthalmol 137 (2004) 496-503
3. Cohen S.Y., Laroche A., Leguen Y., Soubrane G., and Coscas G.J. Etiology of choroidal neovascularization in young patients. Ophthalmology 103 (1996) 1241-1244
4. Brown J F., Folk J.C., Reddy C.V., and Kimura A.E. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 103 (1996) 1100-1105
5. Loo R.H., Scott I.U., Flynn Jr. H.W., et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22 (2002) 19-24
6. Ho A.C., Yannuzzi L.A., Pisicano K., and Derosa J. The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology 102 (1995) 782-789
7. Spaide R.F., Martin M.L., Slakter J., et al. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 134 (2002) 62-68
8. Mimouni K.F., Bressler S.B., and Bressler N.M. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children. Am J Ophthalmol 135 (2003) 900-902
9. Chan W.M., Lam D.S., Lai T.Y., et al. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol 136 (2003) 836-845
10. Chan W.M., Lam D.S., Wong T.H., et al. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 110 (2003) 2395-2402
11. Ergun E., Tittl M., and Stur M. Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol 122 (2004) 37-41
12. Spaide R.F., Freund K.B., Slakter J., Sorenson J., Yannuzzi L.A., and Fisher Y. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22 (2002) 545-549
13. Rogers A.H., Duker J.S., Nichols N., and Baker B.J. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 110 (2003) 1315-1320
14. Postelmans L., Pasteels B., Coquelet P., et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm 13 (2005) 361-366
15. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., and Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37 (1996) 855-868
16. Kvanta A., Algvere P.V., Berglin L., and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37 (1996) 1929-1934
17. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med 351 (2004) 2805-2816
18. Rosenfeld P.J. Intravitreal avastin: the low cost alternative to lucentis?. Am J Ophthalmol 142 (2006) 141-143
19. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
20. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., and Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
21. Spaide R.F., Laud K., Fine H.F., et al. Intravitral bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
22. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
23. Bashshur Z.F., Bazarbachi A., Schakal A., Haddad Z.A., El-Haibi C.P., and Noureddin B.N. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
24. Yamamoto I., Rogers A.H., Reichel E., Yates P.A., and Duker J.S. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91 (2007) 157-160
25. Holladay J.T. Proper method for calculating average visual acuity. J Refract Surg 13 (1997) 388-391
26. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
27. Michels S., Rosenfeld P.J., Puliafito C.A., Marcus E.N., and Venkatraman A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
28. Nguyen Q.D., Shah S., Tatlipinar S., Do D.V., Anden E.V., and Campochiaro P.A. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 89 (2005) 1368-1370
29. Fung A.E., Rosenfeld P.J., and Reichel E. The international intravitral bevacizumab safety survey. Using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
30. Spitzer M.S., Wallenfels-Thilo B., Sierra A., et al. Antiproliferative and cytotoxic properties of bevacizumab (avastin) on different ocular cells. Br J Ophthalmol 90 (2006) 1316-1321
31. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 270-274
32. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
33. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
34. Reichel E. Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment?. Ophthalmic Surg Lasers Imaging 36 (2005) 270-271